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Background: Recent studies have focused on the diagnostic and prognostic significance of CD24 and CD44
expression in human cancers. This study aimed to explore changes in CD44 and CD24 expression levels in patients
with gastric cancer and to assess their prognostic values.
Methods: CD44 and CD24 expression levels were investigated immunohistochemically in tumor samples from 290
patients with non-cardia gastric adenocarcinoma, of whom 77 had paired adjacent normal gastric mucosa. CD24 and
CD44 mRNA levels were determined by quantitative polymerase chain reaction in 34 patients. Serum anti-Helicobacter
pylori IgG was detected by enzyme-linked immunosorbent assay. Relationships between CD44 and CD24 protein
expression levels and tumor parameters were analyzed and their prognostic values were evaluated by Cox proportional
hazards models.
Results: CD24 and CD44 expression levels were significantly higher in patients with gastric cancer compared with
those in paired controls (45.5% vs. 0.0%, and 61.0% vs. 0.0%, P < 0.001). Among 290 patients, the overall survival rate
was significantly higher in CD44(−) compared with CD44(+) patients (log-rank test, P = 0.035). However, there was no
significant correlation between CD24 expression and overall survival time (log-rank test, P = 0.115). Multivariate
regression analysis indicated that positive CD44 expression (P = 0.029), TNM staging (P < 0.001), and lymphovascular
invasion (P = 0.016), but not CD24 expression (P = 0.065), were independent prognostic factors in gastric cancer.
Conclusions: Individual expression of CD44 was associated with poor survival in patients with gastric carcinoma.
Keywords: CD44, CD24, Prognosis, Gastric cancer, Expression, Helicobacter pyloriBackground
Gastric cancer is the third most common cancer in
China. Despite improvements in surgical techniques and
the development of new chemotherapeutic regimens,
there were 989,600 new cases, and more than 738,000
deaths worldwide in 2008. Half of these cases and deaths
were estimated to occur in China. The prognosis for pa-
tients with advanced gastric cancer remains poor, even
after curative surgery [1-3]. Although many studies have
investigated molecular markers for gastric cancer, the
mechanisms of carcinogenesis remain obscure. Interac-
tions between genetic susceptibility variants, molecular* Correspondence: jiangjing19702000@jlu.edu.cn
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unless otherwise stated.alterations, and environmental and lifestyle factors are
known to contribute to the development of gastric cancer.
TNM staging of gastric carcinoma is used to judge the
prognosis, but there is currently no good molecular-based
biomarker that can serve as a useful prognostic predictor
for advanced gastric cancer [4]. Both CD24 and CD44 are
known to contribute to cellular signaling and cell adhe-
sion, and their roles in carcinogenesis have been investi-
gated. CD24 is a mucin-like cell surface protein shown to
be associated with malignancy in numerous human-tissue
studies [5]. CD44 is a transmembrane glycoprotein in-
volved in cellular adhesion, which has also been shown to
be highly expressed in gastric adenocarcinoma [6].
Sheridan et al. demonstrated that the CD44(+)/CD24(−)
phenotype of breast cancer cells was associated with inva-
sive properties and poor prognosis [7]. Cancer stem cells. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cer cell lines in several studies [8], and CD44(+)CD24(+)
cells have been shown to define a highly tumorigenic,
gastric cancer cell population with properties of self-
regeneration and multi-lineage differentiation [9]. Weichert
et al. showed that cytoplasmic expression of CD24 was in-
dependently correlated with shortened survival in colorec-
tal cancer [10]. Yong et al. recently investigated CD44/
CD24 expression in a retrospective analysis of patients
with recurrent gastric cancer, but found no associations
between individual or combined expression of CD24 and
CD44 and the recurrence of gastric cancer [11]. Based on
these previous studies, we hypothesized that CD24 and
CD44 expression might be correlated with gastric cancer
prognosis. The aim of this study was therefore to evaluate
the expression levels of CD24 and CD44 in gastric cancer
and to evaluate their possible predictive relevance for fu-
ture clinical practice. Helicobacter pylori infection is con-
sidered a risk factor for gastric adenocarcinoma, and a
recent study reported that H. pylori, via CagA, unveiled
CSC-like properties in gastric epithelial cells [12]. We
therefore also investigated the correlation between H.
pylori infection and CD24/CD44 expression.
Methods
Participants
A total of 290 patients (221 men and 69 women) with
non-cardia gastric adenocarcinoma who underwent radical
operation (D1+ or D2) at the First Hospital of Jilin Univer-
sity were enrolled in this study between August 2000 and
December 2010. The patients did not receive any pre-
operative chemo-radiotherapy. Postoperative chemother-
apy was administered to all patients with stages II, III, and
IV tumors. The diagnosis of gastric cancer was made on
the bases of morphologic and immunohistochemical find-
ings, evaluated independently by two pathologists (MJ and
YW). Tumor samples were collected at surgery. Histo-
pathological classification and grades of adenocarcinoma
were defined according to the Laurén classification [13]
and World Health Organization (WHO) classification
2010 [14]. They included papillary adenocarcinoma (n =
4), tubular adenocarcinoma (n = 252), mucinous adenocar-
cinoma (n = 27), and poorly cohesive carcinomas (signet
ring cell carcinoma) (n = 7) according to WHO classifica-
tion 2010. Adjacent normal gastric epithelial samples were
also collected from 77 patients for comparison. Patient
ages were from 32 to 87 years, with a median age of
64 years. Written informed consent was obtained from all
the patients and the study protocol was approved by the
Ethics Committee of the First Hospital of Jilin University.
Immunohistochemistry
Tissue blocks were constructed using a tissue array
(Minicore; Alphelys Impasse Paul Langevin, Plaisir, France).Sections (4 μm thick) were cut, deparaffinized, and stained
using a streptavidin-biotin immunoperoxidase technique.
The sections were then incubated with an anti-human
CD24 polyclonal antibody (1:100 diluted, sc-7034; Santa
Cruz, USA) and a CD44 monoclonal antibody (1:50 diluted,
MA1-81995; Thermo Fisher Scientific Inc., Chicago, IL,
USA), respectively. 3, 3-Diaminobenzidine was employed
as a chromogen. Sections were counterstained with
hematoxylin. Slides treated with IgG isotypes instead of
primary antibodies were used as negative controls. The
stained slides were evaluated independently by two pa-
thologists (MJ and YW) who were blinded to the clinical
data and outcomes. Staining intensity and percentages of
cells stained at a specific magnitude of intensity were
assessed using the widely accepted HSCORE system.
The HSCORE was calculated using the following equa-
tion: HSCORE = ∑Pi(i) (I = 0, 1, 2, 3, Pi = 0–100%), where
i represents the staining intensity, i.e., 0 = no staining, 1 =
weak staining, 2 =moderate staining, and 3 = strong stain-
ing. (Additional file 1: Figure S1) Photographs of the refer-
ence intensities are shown in the supplemental data.
Given that Pi represents the percentage of stained cells
with intensities varying from 0 to 100%, the final HSCORE
varied from 0 to 300. The percentages of positive cells were
counted in at least 50 fields by examining at least 1000 cells
under a microscope, using a 40× objective lens. The ex-
pression levels of CD24 and CD44 were classified as nega-
tive (HSCORE < 30) and positive (HSCORE ≥ 30). Cut-off
values for CD24 and CD44 (HSCORE < 30) were modified
according to the results of previous studies [11,15].
Reverse transcription–polymerase chain reaction
quantification of CD24 and CD44
Expression levels of CD24 and CD44 mRNA were deter-
mined in 34 patients with gastric cancer. Briefly, RNA was
extracted from stomach tissues using an RNA Isolation
Kit (Axygen, CA, USA) according to the manufacturer’s
guidelines. After DNase treatment, first-strand cDNA was
synthesized using a cDNA synthesis kit (Roche, Basel,
Switzerland). Quantitative polymerase chain reaction of
CD24 (forward primer: AAA CAA CAA CTG GAA CTT
CAA GTA ACT C, reverse primer: GGT GGT GGC ATT
AGT TGG ATT T) and CD44v6 (forward primer: TCC
CTG CTA CCA ATA GGA ATG ATG, reverse primer:
GGT CAC TGG GAT GAA GGT CC) was performed
using the Light Cycler 480 system (Roche). Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was quantified as
an endogenous RNA control (forward primer: TGC ACC
ACC AAC TGC TTA GC, reverse primer: GGC ATG
GAC TGT GGT CAT GAG).
Determination of H. pylori infection
Blood samples were collected from 103 patients to deter-
mine the presence of H. pylori infection before surgery.
A B
Figure 1 Visualization of CD24 and CD44 expression in gastric cancer cells by immunohistochemistry. CD24 (A) and CD44 (B) immunostaining
in the membrane of gastric carcinoma cells.
Figure 2 mRNA expression levels of CD24 and CD44.
Quantification by reverse transcription-polymerase chain reaction
showed that CD24 (A) and CD44 (B) levels were significantly
higher in immunohistochemically positive compared with
immunohistochemically negative groups, respectively. *, P < 0.001.
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immunosorbent assay (Biohit, Helsinki, Finland). Briefly,
samples with titers above the cut-off value of 30 EIU were
considered as positive for H. pylori infection, as described
previously [16].
Statistical analysis
The HSCOREs for CD24 and CD44 expression were
presented as medians (interquartile range). Mann–
Whitney U, Kruskal–Wallis H, and Wilcoxon signed
rank tests were used to compare results between
groups. The Kaplan–Meier method was used to esti-
mate the overall survival rate, and survival differences
were analyzed using log-rank tests. A Cox propor-
tional hazards model was used to calculate the rela-
tive risks and corresponding 95% confidence intervals
(CI), after adjusting for age, sex, lymphovascular inva-
sion, and TNM staging. Analyses were performed
using SPSS software 18.0 (SPSS Inc., USA). All statis-
tical tests were two-tailed and P values < 0.05 were
considered to be statistically significant.
Results
CD24 and CD44 expression levels in gastric cancer
CD24 and CD44 expression were detected in the mem-
brane of cancer cells in gastric cancer samples (Figure 1).
Weak staining for both CD24 and CD44 was also ob-
served in the nucleus of gastric cancer cells. All negative
controls demonstrated negligible background staining.
Among 77 paired samples, CD24(+) and CD44(+) staining
results were found in 35/77 (45.5%) and 47/77 (61.0%) of
the gastric cancer samples, respectively. However, the
paired normal gastric epithelial cells showed negative ex-
pression of CD24 and CD44. mRNA expression levels of
both CD24 and CD44 were significantly higher in immu-
nohistochemically positive compared with immunohisto-
chemically negative groups. The mRNA expression levels
of CD24 and CD44 were consistent with the immunohis-
tochemistry results in gastric cancer (Figure 2).
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clinicopathologic parameters
Patients with lymphovascular invasion had significantly
higher rates of CD44 positivity than those without invasion












Intestinal type (n=104) 42(40.3)
Diffuse type (n=186) 77(41.3)
WHO classification





Mucinous adenocarcinoma (n=27) 7(25.9)





















Died (n=119) 55(46.2)analyzed according to age, sex, tumor differentiation, depth
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ever, there were no significant differences in CD24/CD44
expression levels in relation to these parameters. The clinical
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Follow-up information was available for all 290 patients
for periods of 3–135 months (median 41 months). No pa-
tient died of postoperative complications within 30 days of
the beginning of the study period, but 119 (41.0%) patients
died during the follow-up period. The overall survival
time was significantly longer in CD44(−) compared with
CD44(+) patients (Figure 3A; log-rank test, P = 0.035). Al-
though patients with CD24(−) tumors showed a trend to-
wards longer overall survival trend, the difference was not
significant (Figure 3B; log-rank test, P = 0.115). TNM stage
and lymphovascular invasion were significantly related to
postoperative survival time (Figure 3C,D).
CD44 expression was an independent prognostic marker
After adjusting for sex, age, TNM stage, and lymphovascu-
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Figure 3 Factors affecting overall survival in patients with gastric can
overall survival time (B). However CD44 expression (A), TNM staging (C), an
survival in gastric cancer.risk of gastric cancer-related death compared with CD44(−)
patients (odds ratio (OR) = 1.57; 95% CI: 1.05–2.36; P =
0.029). Compared with patients who were CD24(−),
CD24(+) patients had a higher likelihood of shorter
overall survival, though the difference was not significant
(OR = 1.41; 95% CI: 0.98–2.02; P = 0.065). Multivariate
analyses identified CD44 expression, TNM stage, and
lymphovascular invasion as independent prognostic fac-
tors of poor patient survival in gastric cancer (Table 2).
CD24/CD44 expression levels and H. pylori infection
Helicobacter pylori infection was detected in 67 of the
103 (65.4%) gastric cancer patients tested. However,
there was no correlation between H. pylori infection and
CD44 expression (P = 0.815), and no significant associ-
ation between H. pylori infection and CD24 expression










































cer. Note no significant correlation between CD24 expression and
d lymphovascular invasion (D) were significantly associated with poor
Table 2 Multivariate analysis with Cox proportional
hazards model for prediction of overall survival in
patients with gastric cancer
Relative risk (95% CI) P value*
CD44 expression
Negative (n=112) Reference
Positive (n=178) 1.57(1.05-2.36) 0.029
CD24 expression
Negative (n=173) Reference
Positive (n=117) 1.41(0.98-2.02) 0.065
TNM staging
I (n=23) Reference
II (n=47) 1.69(0.46-6.24) 0.433
III (n=187) 4.32(1.33-14.01) 0.015
IV (n=33) 14.53(4.27-49.41) <0.001
Lymph-vascular invasion
Absent (n=134) Reference
Present (n=156) 1.60(1.09-2.35) 0.016
*Cox proportional hazards model, adjusted for gender, age,venous infiltration,
TNM staging.
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Several recent studies have focused on the diagnostic
and prognostic significance of CD24 and CD44 expres-
sion in human cancers [17-19], and the roles of CD24
and CD44 in gastric carcinoma have also been explored
[6,11,20,21]. Takahashi et al. reported that CD24 up-
regulation was significantly associated with depth of in-
vasion and high pathological stage in 173 patients with
gastric cancer [22]. The frequency of CD44 expression
in gastric cancer varies widely from 31 to 72%. Ozmen
et al. reported significant correlations between CD44
over-expression and perineural invasion and lymph node
positivity in gastric cancers [23]. The present study sim-
ultaneously analyzed CD24 and CD44 expression levels
independently and showed that positive expression of
CD44 alone, but not CD24, was associated with poor
survival in gastric carcinoma. No CD24(+) or CD44(+)
staining was found in normal gastric surface epithelium
in the present study, though Bessède et al. did detect
CD44 expression in normal gastric mucosa [12]. Further
studies are needed to explain this apparent discrepancy.
CD24 is a mucin-type glycosylphosphatidylinositol-
linked cell surface protein that is expressed in develop-
ing or regenerating tissue, and in ovarian cancer and
hepatocellular carcinoma [20,24]. Previous investigation
of the correlation between CD24/CD44 expression and
gastric cancer revealed that CD24(+) patients had a
higher likelihood of gastric cancer recurrence than
CD24(−) patients [11]. However, the biological function
of CD24 in carcinogenesis remains unknown. Previous
studies observed relationships between high CD24 ex-
pression and lymph node metastasis, venous invasion,and lymphatic invasion. However, although the present
study found a trend towards shorter survival in CD24(−)
compared with CD24(+) patients, the difference was not
significant. Duckworth et al. detected CD24 expression
in gastric parietal cells and showed that it regulated
apoptosis and the response to Helicobacter felis infection
in a mouse model [25]. However, the current study
found no significant association between Helicobacter
infection and CD24 expression. One possible explan-
ation for the significant association between CD44 and
survival may be related to the stem cell function of
CD44(+) cells [26-29]. In 2009, Takaishi et al. first dem-
onstrated the existence of CD44(+) cells endowed with
stem cell properties in gastric tumors. They reported
that CD44(+) gastric cancer cells showed the stem cell
characteristics of self-renewal and the ability to form dif-
ferentiated progeny and give rise to CD44(−) cells.
Takaishi et al. further verified CD44 as a cell surface
marker of gastric CSCs in several human gastric cancer
cell lines, and demonstrated that CD44(+) gastric cancer
cells showed increased resistance to chemotherapy- or
radiation-induced cell death [29]. Liu et al. reported that
CD44 was a direct and relevant downstream target of
miR-34a in prostate cancer. CD44 protein levels were
decreased in cells over-expressing miR-34a, and knock
down of CD44 functionally mimicked the miR-34a ef-
fects of inhibition of tumor development and metastasis
[30]. We therefore considered that higher expression of
CD44 in gastric cancer cells may represent a higher per-
centage of CSCs, thus explaining why CD44(+) patients
demonstrate poorer overall survival than CD44(−) pa-
tients. Further studies are warranted to investigate the
mechanisms of miRNA regulation of CSCs.
Conclusions
In conclusion, expression of CD44 was associated with
poor survival in patients with gastric carcinoma. This
suggests that CD44 may be a clinically useful prognostic
marker, and may also represent a useful therapeutic tar-
get. However, the functions of CD24 and CD44 in gas-
tric carcinogenesis remain unclear [31,33], and further
studies are needed to clarify their roles.
Additional file
Additional file 1: Figure S1. Photographies of the CD44
immunohistochemistry staining intensities: 0, 1, 2, and 3.
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